文献速递消化与肝胆胰病理细胞病理与分子病理

联合囊液辅助检测、抑制素免疫组化与细针活检提高胰腺浆液性囊腺瘤诊断率

Improving diagnostic yield of pancreatic serous cystadenoma with cyst fluid ancillary testing, adjunct immunohistochemistry, and additional fine-needle biopsy sampling.
PubMed 文献 · Cancer Cytopathol · 2024-03-07

该回顾性研究纳入31例经组织学确诊的胰腺浆液性囊腺瘤(SCA)病例,评估囊液辅助检测、抑制素免疫组化与联合细针活检(FNB)对诊断率的作用。结果显示原细胞学诊断多为非黏液性囊肿等非确诊结论,囊液CEA均低、KRAS均野生型;同步FNA与FNB的15例中FNB确诊率明显高于FNA。

要点

  • 囊液CEA低水平与KRAS野生型可见于SCA,但单独依靠其仍难以确诊SCA。
  • 抑制素免疫组化在7例受检细胞块中6例阳性,或有助于选择性病例诊断。
  • 同步FNA与FNB的15例中,FNB确诊SCA者13例(87%),FNA仅1例(7%)。

核心结论

  • 研究提示即使结合囊液CEA水平与KRAS突变分析等辅助检测,FNA诊断SCA仍具挑战性。
  • 辅助抑制素免疫染色可能有助于改善选择性SCA病例的细胞学诊断。
  • FNB在SCA的明确诊断上似乎优于FNA。

研究设计与样本

  • 回顾性研究,纳入经组织学确诊为SCA的细胞学病例,共31例,来自13例男性与18例女性患者,平均年龄65岁。
  • 回顾临床特征、FNA囊液生化与分子分析结果及FNB表现。
  • 对FNA细胞块回顾性行抑制素免疫组化,并比较同步FNA与FNB活检病例的诊断情况。

主要发现

  • 原细胞学诊断:无法诊断6例(19%)、未见恶性细胞/囊内容物7例(23%)、异型细胞3例(10%)、非黏液性囊肿11例(35%)、浆液性囊腺瘤4例(13%)。
  • 囊液癌胚抗原(CEA)分析17例,均显示低CEA水平(<192 ng/mL)。
  • 分子检测14例,均为野生型KRAS。
  • FNA细胞块抑制素免疫组化7例中6例阳性。
  • 同步FNA与FNB活检15例中,FNA诊断SCA仅1例(7%),FNB诊断SCA 13例(87%)。

关键数值与推荐

  • 囊液CEA低水平定义为<192 ng/mL,17例受检者均符合。
  • 分子检测14例均为野生型KRAS。
  • 抑制素免疫组化在7例FNA细胞块中6例阳性。
  • 同步FNA与FNB的15例中,FNA确诊SCA 1例(7%),FNB确诊SCA 13例(87%)。

临床怎么用

  • 对疑诊胰腺SCA的病例,可考虑联合囊液CEA与KRAS检测辅助评估,但不应单独依赖其确诊。
  • 对选择性病例可在细胞块上加做抑制素免疫组化以辅助细胞学诊断。
  • 在条件允许时联合FNB取材,可能提高SCA的明确诊断率。

局限性

  • 为回顾性研究,样本量有限(31例),部分辅助检测仅覆盖部分病例。
  • 抑制素免疫组化为回顾性检测,检测病例数少(7例)。
  • 同步FNA与FNB比较仅基于15例,结论需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fine-needle aspiration (FNA) diagnosis of pancreatic serous cystadenoma (SCA) remains challenging. This retrospective study aimed to evaluate the roles of cyst fluid ancillary testing and combined fine-needle biopsy (FNB) in improving the diagnostic yield. METHODS: The authors retrospectively reviewed cytology cases that were histologically confirmed SCAs. Clinical features and FNA cyst fluid biochemical and molecular analysis results along FNB findings were reviewed. RESULTS: The study cohort included 31 cases from 13 male and 18 female patients with a mean age of 65. The original cytologic diagnoses were nondiagnostic (n = 6, 19%), negative for malignant cells/cyst contents (n = 7, 23%), atypical cells (n = 3, 10%), nonmucinous cyst (n = 11, 35%), and serous cystadenoma (n = 4, 13%). Cyst fluid carcinoembryonic antigen (CEA) analysis was performed in 17 cases, all of which showed a low CEA level (<192 ng/mL). All 14 cases with molecular testing showed a wild-type KRAS. Inhibin immunohistochemistry was retrospectively performed on the FNA cell blocks, inhibin was positive in six of seven cases tested. In 15 cases with concurrent FNA and FNB biopsies, the diagnosis of SCA was seen in only one FNA case (7%) but 13 FNB cases (87%). CONCLUSIONS: This study suggests that FNA diagnosis of SCA remains challenging even with ancillary testing including cyst fluid CEA level and KRAS mutation analysis. Adjunct inhibin immunostaining may help improve the cytologic diagnosis of selective SCA cases. FNB appears superior to FNA for a definite diagnosis of SCA.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Wang X, Zhang X, Hui P, et al. Improving diagnostic yield of pancreatic serous cystadenoma with cyst fluid ancillary testing, adjunct immunohistochemistry, and additional fine-needle biopsy sampling. Cancer Cytopathol. 2024. PMID: 38450993. doi:10.1002/cncy.22808

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。